Skip to main content

CORRECTION article

Front. Med., 26 July 2023
Sec. Gastroenterology
Volume 10 - 2023 | https://doi.org/10.3389/fmed.2023.1256685

Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report

This article is a correction to:

  1. Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report

    1. Read original article
\r\nNingning Yan&#x;Ningning Yan1†Ziheng Zhang&#x;Ziheng Zhang1†Sanxing GuoSanxing Guo1Shujing Shen Shujing Shen2*Xingya Li Xingya Li1*
  • 1Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • 2Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

A corrigendum on
Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report

by Yan, N., Zhang, Z., Guo, S., Shen, S., and Li, X. (2023). Front. Med. 10:1130012. doi: 10.3389/fmed.2023.1130012

In the published article, the author names were incorrectly written as “Ning Yan, Zi Zhang, San Guo, Shu Shen, Xing Li”. The correct spellings are “Ningning Yan, Ziheng Zhang, Sanxing Guo, Shujing Shen, Xingya Li”.

In the published article, there was a mistake in the Author contributions. The correct Author contributions appears below.

Author contributions

NNY, ZHZ, SJS, and XYL wrote the manuscript. NNY, ZHZ, and SXG prepared Figures and Tables. All authors have reviewed the manuscript and gave their consent to publication. All authors contributed to the article and approved the submitted version.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: liver cancer, tyrosine kinase inhibitors, MET, savolitinib, MET-TKI

Citation: Yan N, Zhang Z, Guo S, Shen S and Li X (2023) Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report. Front. Med. 10:1256685. doi: 10.3389/fmed.2023.1256685

Received: 11 July 2023; Accepted: 13 July 2023;
Published: 26 July 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Yan, Zhang, Guo, Shen and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Shujing Shen, shensj_radiology@163.com; Xingya Li, fcclixy1@zzu.edu.cn

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.